Pfizer recognizes the public concern in relation to COVID-19, which continues to evolve.
Click here to learn how we are responding.

EXPANDING OPTIONS FOR PATIENT CARE

The Pfizer Oncology Biosimilars Portfolio

Select any of the biosimilar products to access helpful resources that may benefit your practice. You'll find Prescribing Information and Important Safety Information, clinical data, and support on how to implement patient communications, benefits verification, medication ordering, and much more.
Visit this site regularly to ensure you have the latest updates and newest resources as they are added.

*Biosimilar means that the biological product is approved based on data demonstrating that it is highly similar to an FDA-approved biological product, known as a reference product, and that there are no clinically meaningful differences between the biosimilar and the reference product.1-6

References:

1. NIVESTYM [prescribing information]. New York, NY: Pfizer Inc.; April 2021. 2. NYVEPRIA [prescribing information]. New York, NY: Pfizer Inc.; April 2021. 3. RETACRIT [prescribing information]. New York, NY: Pfizer Inc.; August 2020. 4. RUXIENCE [prescribing information]. New York, NY: Pfizer Inc.; May 2020. 5. TRAZIMERA [prescribing information]. New York, NY: Pfizer Inc.; November 2020. 6. ZIRABEV [prescribing information]. New York, NY: Pfizer Inc.; May 2021.

NIVESTYM, RETACRIT, RUXIENCE, TRAZIMERA, and ZIRABEV are registered trademarks of Pfizer Inc.
NYVEPRIA is a trademark of Pfizer Inc.

Avastin and Herceptin are registered trademarks of Genentech, Inc. Epogen, Neulasta, and Neupogen are registered trademarks of Amgen Inc. Procrit is a registered trademark of Janssen Products, LP. Rituxan is a registered trademark of Biogen, Inc.